

Members of the [Collaborative for Cannabinoid Science & Safety](#) would like to invite you its **in-person Congressional briefing on May 31st**(see below invitation). CCSS launched in 2020 with a mission to convene diverse stakeholders interested in supporting and promoting a science-based regulatory pathway for CBD-containing products that protects patients and consumers.

Why should you care? The Food and Drug Administration recently [announced](#) that existing regulatory frameworks for foods and supplements are not appropriate for CBD, and that it will work with Congress on a new path forward. Learn about what scientists, consumers, and healthcare providers think.

[Please register at this link.](#)

If you have any questions about CCSS, I'd be happy to talk before/after the event. Thanks!

With support from Chairwoman McMorris Rodgers,
the Collaborative for Cannabinoid Science and Safety (CCSS) invites you to a

LUNCH BRIEFING

on **Cannabinoid-Containing Products:
Risks of the Unregulated Marketplace**

May 31st, 2023 | 11:00-12:00 p.m. EST

2123 RAYBURN (E&C Hearing Room)

The availability of cannabinoid-containing products following the passage of the 2018 Farm Bill has increased exponentially, partially driven by demand and interest in its potential health and wellness benefits. However, questions remain on the legality, quality, safety, and effectiveness of many of these products. Our panel experts will discuss:

- the scientific and legal differences between cannabis, hemp, and cannabinoids
- the perceived benefits and known risks of cannabinoid-containing products
- the historic and current regulatory and legislative environment for these products
- policy recommendations that would create an environment that fosters development and innovation for these products while protecting consumer safety

Speakers:

- Carmen Witsken, Executive Fellow, American Society of Consultant Pharmacists (ASCP)
- Mark Bolton, Head of Global Public Policy & Sr. Legal Counsel, Jazz Pharmaceuticals
- Sally Greenberg, Executive Director, National Consumers League (NCL)
- Joe Hill, Director of Government Affairs, US Pharmacopeia (USP)

This briefing will be widely attended and complies with Senate and House ethics rules.

If you have any questions about this briefing or would like to learn more about CCSS, please email Nisha Quasba (Nisha.Quasba@faegredrinker.com) or Charlie Pritchard (charles.pritchard@faegredrinker.com).